Luminary Therapeutics is a pre-clinical cell therapy company focused on developing next generation cell therapies using a non-viral
approach that reduces the cost, complexity, and safety concerns associated with virus-based cell therapies. Our lead candidate LMY920 is a proprietary BAFF CAR that targets 3 unique receptors, providing several advantages over current CAR-T products. LMY-920
has completed all pre-clinical safety, dosing and GLP toxicity studies, and is on track to enter clinical trials in Q1-2022. In addition,
Luminary has developed a novel Universal Receptor technology that is poised to disrupt conventional approaches by expanding the
scope of binder moieties and allowing “on/off” control over engineered cells.